# INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Source: https://onco.cc/trials/nct06295731/  
OnCo record `nct06295731` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing INBRX-106 in head and neck squamous cell carcinoma, active and no longer recruiting.

## Summary

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC is a phase 2/3 interventional study registered as NCT06295731, led by Inhibrx Biosciences, and active but no longer recruiting on the registry. Official title: A Phase 2/3, Randomised Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN). Planned enrolment is 410 participants (estimated). The study started in 2024-05-14 and primary completion is expected in 2029-05. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: HexAgon-HN
- Tags: ctgov-ingest
- Registry id: NCT06295731
- Phase: 2/3
- Setting: A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)
- Sponsor: Inhibrx Biosciences
- Enrolled: 410

## Sources

- ClinicalTrials.gov NCT06295731: https://clinicaltrials.gov/study/NCT06295731

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- drugs: [INBRX-106](https://onco.cc/drugs/inbrx-106/)
- companies: [Inhibrx Biosciences](https://onco.cc/companies/inhibrx/)

---
JSON: https://onco.cc/api/v1/entities/nct06295731.json